Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,170 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Mirikizumab as Induction and Maintenance Therapy for Ulcerative Colitis.
D'Haens G, Dubinsky M, Kobayashi T, Irving PM, Howaldt S, Pokrotnieks J, Krueger K, Laskowski J, Li X, Lissoos T, Milata J, Morris N, Arora V, Milch C, Sandborn W, Sands BE; LUCENT Study Group. D'Haens G, et al. Among authors: morris n. N Engl J Med. 2023 Jun 29;388(26):2444-2455. doi: 10.1056/NEJMoa2207940. N Engl J Med. 2023. PMID: 37379135 Clinical Trial.
Disease Burden and Patient-Reported Outcomes Among Ulcerative Colitis Patients According to Therapy at Enrollment Into CorEvitas' Inflammatory Bowel Disease Registry.
Cross RK, Naegeli AN, Harrison RW, Moore PC, Mackey RH, Crabtree MM, Lemay CA, Arora V, Morris N, Sontag A, Kayhan C, Korzenik JR. Cross RK, et al. Among authors: morris n. Crohns Colitis 360. 2022 Mar 8;4(3):otac007. doi: 10.1093/crocol/otac007. eCollection 2022 Jul. Crohns Colitis 360. 2022. PMID: 36777423 Free PMC article.
Changes in health-related quality of life and associations with improvements in clinical efficacy: a Phase 2 study of mirikizumab in patients with ulcerative colitis.
Dubinsky MC, Jairath V, Feagan BG, Naegeli AN, Tuttle J, Morris N, Shan M, Arora V, Lissoos T, Agada N, Hibi T, Sands BE. Dubinsky MC, et al. Among authors: morris n. BMJ Open Gastroenterol. 2023 Mar;10(1):e001115. doi: 10.1136/bmjgast-2023-001115. BMJ Open Gastroenterol. 2023. PMID: 37001911 Free PMC article. Clinical Trial.
Mirikizumab Improves Quality of Life in Patients With Moderately-to-Severely Active Ulcerative Colitis: Results From the Phase 3 LUCENT-1 Induction and LUCENT-2 Maintenance Studies.
Sands BE, Feagan BG, Hunter Gibble T, Traxler KA, Morris N, Eastman WJ, Schreiber S, Jairath V, Long MD, Armuzzi A. Sands BE, et al. Among authors: morris n. Crohns Colitis 360. 2023 Nov 7;5(4):otad070. doi: 10.1093/crocol/otad070. eCollection 2023 Oct. Crohns Colitis 360. 2023. PMID: 38034882 Free PMC article.
Extended Induction and Prognostic Indicators of Response in Patients Treated with Mirikizumab with Moderately to Severely Active Ulcerative Colitis in the LUCENT Trials.
D'Haens G, Higgins PDR, Peyrin-Biroulet L, Sands BE, Lee S, Moses RE, Redondo I, Escobar R, Gibble TH, Keohane A, Morris N, Zhang X, Arora V, Kobayashi T. D'Haens G, et al. Among authors: morris n. Inflamm Bowel Dis. 2024 Jan 25:izae004. doi: 10.1093/ibd/izae004. Online ahead of print. Inflamm Bowel Dis. 2024. PMID: 38271613
Efficacy and safety of mirikizumab as induction and maintenance therapy for Japanese patients with moderately to severely active ulcerative colitis: a subgroup analysis of the global phase 3 LUCENT-1 and LUCENT-2 studies.
Kobayashi T, Matsuoka K, Watanabe M, Hisamatsu T, Hirai F, Milata J, Li X, Morris N, Arora V, Ishizuka T, Matsuo K, Satoi Y, Milch C, Hibi T. Kobayashi T, et al. Among authors: morris n. Intest Res. 2024 Apr;22(2):172-185. doi: 10.5217/ir.2023.00043. Epub 2024 Apr 25. Intest Res. 2024. PMID: 38720466
1,170 results